Molecular Therapy - Nucleic Acids

Slides:



Advertisements
Similar presentations
Products > Liver In Vivo Transfection Kit
Advertisements

Volume 50, Issue 3, Pages (March 2009)
Darren M Brown, Erkki Ruoslahti  Cancer Cell 
Aldehyde Dehydrogenase 1A1 Possesses Stem-Like Properties and Predicts Lung Cancer Patient Outcome  Xiao Li, MD, Liyan Wan, MD, Jian Geng, MD, Chin-Lee.
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 24, Issue 7, Pages (July 2016)
Volume 21, Issue 10, Pages (October 2013)
Development of Cell-Penetrating Asymmetric Interfering RNA Targeting Connective Tissue Growth Factor  Jihye Hwang, Chanil Chang, Ji Hyun Kim, Chang Taek.
Molecular Therapy - Nucleic Acids
Volume 13, Issue 6, Pages (November 2015)
Aldehyde Dehydrogenase 1A1 Possesses Stem-Like Properties and Predicts Lung Cancer Patient Outcome  Xiao Li, MD, Liyan Wan, MD, Jian Geng, MD, Chin-Lee.
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 18, Issue 5, Pages (May 2010)
Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes  Kiyoko Setoguchi, Lin.
Volume 128, Issue 5, Pages (May 2005)
Pei-Tzu Li, M. S. , Chi-Jr Liao, M. S. , Wen-Guey Wu, Ph. D
Volume 14, Issue 4, Pages (October 2006)
Enrichment for Living Murine Keratinocytes from the Hair Follicle Bulge with the Cell Surface Marker CD34  Rebecca J. Morris, Carl D. Bortner, George.
Molecular Therapy - Nucleic Acids
Volume 18, Issue 9, Pages (September 2010)
Volume 21, Issue 12, Pages (December 2013)
Volume 25, Issue 8, Pages (August 2017)
Molecular Therapy - Nucleic Acids
Brian Poligone, Elaine S. Gilmore, Carolina V
Volume 25, Issue 1, Pages (January 2017)
Volume 21, Issue 10, Pages (October 2013)
Volume 16, Issue 12, Pages (December 2008)
Darren M Brown, Erkki Ruoslahti  Cancer Cell 
Ribosomal Protein S3 Gene Silencing Protects Against Cigarette Smoke-Induced Acute Lung Injury  Jinrui Dong, Wupeng Liao, Hong Yong Peh, W.S. Daniel Tan,
Molecular Therapy - Nucleic Acids
Volume 26, Issue 1, Pages (January 2018)
Codon-Optimized P1A-Encoding DNA Vaccine: Toward a Therapeutic Vaccination against P815 Mastocytoma  Alessandra Lopes, Kevin Vanvarenberg, Véronique Préat,
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
HDAC5, a Key Component in Temporal Regulation of p53-Mediated Transactivation in Response to Genotoxic Stress  Nirmalya Sen, Rajni Kumari, Manika Indrajit.
Interleukin-18 and the Costimulatory Molecule B7-1 Have a Synergistic Anti-Tumor Effect on Murine Melanoma; Implication of Combined Immunotherapy for.
Molecular Therapy - Nucleic Acids
Volume 23, Issue 10, Pages (October 2015)
Multiple Functions of the 37/67-kd Laminin Receptor Make It a Suitable Target for Novel Cancer Gene Therapy  Jonathan Scheiman, Jen-Chieh Tseng, Yun Zheng,
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Modular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8+ T-cell Activation Against Tumors  Benjamin J Umlauf, Chin-Ying.
Volume 17, Issue 2, Pages (February 2009)
Molecular Therapy - Methods & Clinical Development
Volume 26, Issue 2, Pages (February 2018)
Volume 18, Issue 3, Pages (March 2010)
Volume 21, Issue 1, Pages (January 2013)
Volume 22, Issue 2, Pages (February 2014)
Volume 20, Issue 3, Pages (March 2012)
Volume 26, Issue 1, Pages (January 2018)
Volume 23, Issue 8, Pages (August 2015)
Therapy-induced senescence of primary cells.
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 13, Issue 6, Pages (November 2015)
Molecular Therapy - Nucleic Acids
MRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma  Yuhua Wang, Lu Zhang, Zhenghong.
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 25, Issue 6, Pages (June 2017)
Rumwald Leo G Lecaros, Leaf Huang, Tsai-Chia Lee, Yih-Chih Hsu 
Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.
Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol
Arati Sridharan, Chetan Patel, Jit Muthuswamy 
Aminoglycoside Enhances the Delivery of Antisense Morpholino Oligonucleotides In Vitro and in mdx Mice  Mingxing Wang, Bo Wu, Sapana N. Shah, Peijuan.
Presentation transcript:

Molecular Therapy - Nucleic Acids Efficient Biodistribution and Gene Silencing in the Lung epithelium via Intravenous Liposomal Delivery of siRNA  Jana McCaskill, Richa Singhania, Melinda Burgess, Rachel Allavena, Sherry Wu, Antje Blumenthal, Nigel AJ McMillan  Molecular Therapy - Nucleic Acids  Volume 2, (January 2013) DOI: 10.1038/mtna.2013.22 Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Biodistribution of siRNA-loaded, DiR-labeled liposome nanoparticles after intravenous (IV) injection in mice. (a) Livers, spleens, and lungs were removed 48 hours after IV administration and analyzed on the fluorescent imager (λex = 720 nm; λem = 790 nm). Scale shows intensity of DiR fluorescence. (b) Quantitative analysis of fluorescence intensity for each individual organ. Results are the mean ± SEM of n = 6 from two independent experiments. Molecular Therapy - Nucleic Acids 2013 2, DOI: (10.1038/mtna.2013.22) Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Microscopic morphologic evaluation of murine lungs after liposome delivery. Mice were injected with a single IV administration of either (a) scrambled control siRNA (ScrM7) or (b) siLamin containing liposomes. At 48 hours after injection, lung tissue was harvested, perfusion fixed, and routine histologic sections were stained with hematoxylin/eosin and imaged at 200×. To investigate inflammation at the molecular level, quantitative real-time PCR was carried to determine the levels of murine (c) IFNβ or (d) TNFα. Mice were treated with siRNA-loaded liposomes (control ScrM7 or siLamin) or untreated and total RNA extracted from lung tissue at the times indicated. Data shown are representative images from n = 8 mice per group from two independent experiments. Molecular Therapy - Nucleic Acids 2013 2, DOI: (10.1038/mtna.2013.22) Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Liposomal delivery to lung cells. (a) Total lung cells were purified 48 hours after a single IV administration of unstained or DiR-stained liposomes. Cells were analyzed by flow cytometry. Delivery was quantified as a percentage of DiR+ cells/total cells. Data shown are mean ± SEM of n = 6 mice per group analyzed in two independent experiments. (b) Representative FACS histogram of unstained and DiR-stained liposomes are shown. (c) Individual cell populations were analyzed by flow cytometry for DiR fluorescence. Delivery was quantified as a percentage of DiR+ cells/total cells in the specific population. Control was mice treated with unstained liposomes. Data shown are mean ± SEM of n = 6 mice per group analyzed in two independent experiments. (d) Gating strategy for the analysis of CD45 and CD326+ cell populations by flow cytometry. (e) Analysis of the CD326+ cell population showing the level of DiR-stained liposome delivery to CD45− epithelial cells and CD45+ immune cells. Delivery was quantified as the percentage of total cells in the specific population. Data shown are ± SEM of n = 4 mice per group from two independent experiments. Molecular Therapy - Nucleic Acids 2013 2, DOI: (10.1038/mtna.2013.22) Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Immunofluorescent evaluation of liposomal delivery to lung tissue. Mice were injected with a single IV administration of (a,d) DiR-stained liposomes, (b) liposomes containing AF750 tagged siRNA, or (c) unstained liposomes. At 48 hours after injection, lung tissue was harvested, sectioned, and stained for CD146, CD326, and DAPI nuclear stain and analyzed via confocal microscopy. Scale bar represents 25 µm. Data shown are representative images from n = 6 mice per treatment group from three independent experiments. Molecular Therapy - Nucleic Acids 2013 2, DOI: (10.1038/mtna.2013.22) Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 siRNA liposome–mediated gene knockdown in murine lung cells in vivo. (a) Lungs were collected at 48 hours after a single IV administration of Lamin A/C or control siRNA (40 µg, ~2.5 mg/kg). Gene expression levels of Lamin A/C were quantified by qRT-PCR as relative expression to β-actin housekeeping gene. Results are the mean ± SEM of n = 9 mice per group from three independent experiments. Significant differences between non-specific control and Lamin A/C siRNAs are indicated (**P < 0.01; Student's t-test). (b) Western blot analysis of Lamin A/C expression in whole lung tissue. Each lane represents the Lamin A/C level in the total lung tissue in each individual mouse. Mice received two doses of Lamin A/C or control siRNA (40 µg/dose) IV and were analyzed 4 days after initial injection. (c) Quantitative analysis of the combined LaminA and C protein levels between treatment and control groups. Results are the mean ± SEM of n = 6 mice per group from two independent experiments. Molecular Therapy - Nucleic Acids 2013 2, DOI: (10.1038/mtna.2013.22) Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions

Figure 6 Knockdown analysis of Lamin A/C in epithelial and endothelial cells. Lungs were collected at 48 hours after a single IV administration of Lamin A/C or control siRNA (40 µg). Cell populations were enriched for CD146+ and CD326+ cells by MACS using positive selection. Gene expression levels of Lamin A/C in (a) CD146 and (b) CD326-enriched cell populations were quantified by qRT-PCR and are depicted as relative expression to β-actin. Results are the mean ± SEM of n = 6 from two independent experiments. Significant differences between non-specific control and Lamin A/C siRNAs are indicated (*P < 0.05, **P < 0.01; Student's t-test). (c) Stem-loop qPCR detection of 5′ Lamin A/C cleavage product in positive control, untreated mice lungs, CD146+ and CD326+ MACS-enriched cells from siLamin A/C or control siRNA–treated mouse lungs. Two mice per treatment were analyzed. The positive control sample was prepared by transfecting TC-1 cells with siLamin A/C for 24 hours. The template negative control (NTC) was prepared by incorporating all of the RT-PCR reagents except the cDNA template. LMW, low molecular weight; MACS, magnetic-activated cell sorting. Molecular Therapy - Nucleic Acids 2013 2, DOI: (10.1038/mtna.2013.22) Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions